Compugen (CGEN) Net Income towards Common Stockholders (2009 - 2026)

Compugen (CGEN) reported Net Income towards Common Stockholders of $7.7 million for Q1 2026, up 7.59% on a YoY basis from $7.1 million in Q1 2025, and down 86.5% sequentially from $56.7 million in Q4 2025.

Compugen (CGEN) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends

Compugen (CGEN) has 18 years of Net Income towards Common Stockholders data on file, last reported at $7.7 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 7.59% year-over-year to $7.7 million; the trailing twelve-month figure through Mar 2026 stood at $35.9 million (up 772.34% YoY), and the FY2025 full-year result was $35.3 million, up 348.35% from the prior year.
  • Net Income towards Common Stockholders fell to $7.7 million in Q1 2026, from $56.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $56.7 million in Q4 2025 to a low of -$28.0 million in Q2 2023.
  • A 5-year average of $1.4 million and a median of -$3.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders sank 198.03% in 2023 and jumped 1027.53% in 2025, its largest moves.
  • Tracing CGEN's Net Income towards Common Stockholders over 5 years: stood at -$3.1 million in 2022, then jumped by 414.13% to $9.7 million in 2023, then sank by 162.98% to -$6.1 million in 2024, then jumped by 1027.53% to $56.7 million in 2025, then plunged by 86.5% to $7.7 million in 2026.
  • Business Quant data shows CGEN's Net Income towards Common Stockholders at $7.7 million in Q1 2026, $56.7 million in Q4 2025, and -$6.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,921.77 Bn 66,921.49 Bn - -625.73
2 Nanobiotix 1,924.26 Bn 1,924.20 Bn - -
3 Akari Therapeutics 975.59 Bn 975.59 Bn - -14.46 Mn
4 BeOne Medicines 471.47 Bn 466.67 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.76 Bn 114.52 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.90 Bn 61.15 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.83 Bn 62.83 Bn - -0.68
8 Argenx Se 55.77 Bn 50.59 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.45 Bn 37.45 Bn - -453.82 Mn
10 Compugen 224.57 Mn 132.82 Mn 352,000.00 7.66 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 7.66 Mn
Dec 31, 2025 56.74 Mn
Sep 30, 2025 -6.90 Mn
Jun 30, 2025 -21.61 Mn
Mar 31, 2025 7.12 Mn
Dec 31, 2024 -6.12 Mn
Sep 30, 2024 10.28 Mn
Jun 30, 2024 -16.62 Mn
Mar 31, 2024 7.26 Mn
Dec 31, 2023 9.71 Mn
Sep 30, 2023 -9.85 Mn
Jun 30, 2023 -28.00 Mn
Mar 31, 2023 9.31 Mn
Dec 31, 2022 -3.09 Mn
Sep 30, 2022 -11.75 Mn
Jun 30, 2022 28.56 Mn
Mar 31, 2022 -9.71 Mn
Dec 31, 2021 -8.65 Mn
Sep 30, 2021 -8.18 Mn
Jun 30, 2021 -9.50 Mn